Research-only: Mito / Fatigue / Readiness (SS-31 + MOTS-C)

B84· Mostly solid

Public • 06 Feb 2026

Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.

← Back Try alternative layout

Buy stack

Research-only: Mito / Fatigue / Readiness (SS-31 + MOTS-C)

endurance fatigue readiness

SS-31 (Elamipretide)

PLACEHOLDER

MODERATE

1mg

MOTS-C

PLACEHOLDER

MODERATE

1mg

No interactions detected

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

Timing optimizations

SS-31 (Elamipretide)

Take ~1h before the intended effect window

Reaches peak plasma concentration in ~1h. Half-life ~3h.

MOTS-C

Take ~30 min before the intended effect window

Reaches peak plasma concentration in ~30 min. Half-life ~2h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

2 items

SS-31 (Elamipretide)Moderate

PLACEHOLDER • Lyophilized •

Clinical data exists in mitochondrial myopathy (endpoint-dependent).

Buy ingredient →

1mg

Exercise performance (short-term, earlier phase 2 dose-escalation)

Moderate

Population: Adults with primary mitochondrial myopathy

Study type: Randomized dose-escalation clinical trial

Dose context: — • Duration: 5 days

An earlier short-course dose-escalation study reported improved exercise performance after 5 days; the larger phase 3 MMPOWER-3 trial did not confirm sustained benefit on primary endpoints.

Citation: Karaa et al., Neurology (2018) — randomized dose-escalation elamipretide in PMM•DOI: 10.1212/WNL.0000000000005255•https://pmc.ncbi.nlm.nih.gov/articles/PMC5890606/

Efficacy & safety — phase 3 primary endpoints not met

Moderate

Population: Adults with primary mitochondrial myopathy (n=218)

Study type: Randomized, double-blind, placebo-controlled phase 3 trial (MMPOWER-3)

Dose context: — • Duration: 24 weeks

MMPOWER-3 found no significant improvement in 6-minute walk test distance or fatigue scores with 40 mg/day subcutaneous elamipretide vs. placebo over 24 weeks in the overall PMM population (Class I evidence of no benefit on primary endpoints). A post-hoc subgroup analysis suggested possible benefit in patients with nuclear DNA variants. Elamipretide was well-tolerated.

Citation: Karaa et al., Neurology (2023) — MMPOWER-3 Randomized Clinical Trial•https://pubmed.ncbi.nlm.nih.gov/37268435/

MOTS-CLow

PLACEHOLDER • Other •

Mostly preclinical metabolic/exercise signaling; limited established human efficacy evidence.

Buy ingredient →

1mg

Running performance under metabolic stress

Low

Population: Mice on high-fat diet (preclinical)

Study type: Animal study

Dose context: — • Duration: Preclinical protocol (see paper)

In mice, MOTS-c treatment improved treadmill running performance under diet-induced metabolic stress & showed metabolic regulatory effects.

Citation: Reynolds et al., Nat Commun (2021) — exercise-induced MOTS-c biology and performance in mice•DOI: 10.1038/s41467-020-20790-0•https://www.nature.com/articles/s41467-020-20790-0

Exercise/metabolic signaling (summary)

Very low

Population: Mostly preclinical

Study type: Review

Dose context: —

Reviews propose metabolic & stress-response roles primarily based on preclinical evidence; no effective method of applying MOTS-c in the clinic has been established as of 2024-2025.

Citation: Ming et al., Front Endocrinol (2023) — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation•https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/

Clinical translation status

Low

Population: Humans (clinical development commentary)

Study type: Review / perspective

Dose context: —

Reviews note that clinical trials to test therapeutic MOTS-c potential are limited/ongoing; overall human efficacy evidence remains early. Blood MOTS-c levels are reported lower in type 2 diabetes & obesity, but therapeutic dosing in humans has not been validated.

Citation: Lee et al., Diabetes Metab J (2023) — MOTS-c, diabetes, and related clinical perspective•https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/